Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.3985
+0.0182 (4.79%)
At close: Jan 22, 2026, 4:00 PM EST
0.4051
+0.0066 (1.66%)
After-hours: Jan 22, 2026, 5:45 PM EST
Sangamo Therapeutics Employees
Sangamo Therapeutics had 183 employees as of December 31, 2024. The number of employees decreased by 222 or -54.81% compared to the previous year.
Employees
183
Change (1Y)
-222
Growth (1Y)
-54.81%
Revenue / Employee
$179,645
Profits / Employee
-$595,131
Market Cap
134.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 183 | -222 | -54.81% |
| Dec 31, 2023 | 405 | -73 | -15.27% |
| Dec 31, 2022 | 478 | 47 | 10.90% |
| Dec 31, 2021 | 431 | 18 | 4.36% |
| Dec 31, 2020 | 413 | 59 | 16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 181 |
| Sutro Biopharma | 178 |
| Seres Therapeutics | 103 |
| Verrica Pharmaceuticals | 71 |
| Spero Therapeutics | 32 |
| Oncolytics Biotech | 28 |
| Cognition Therapeutics | 28 |
| Genelux | 24 |
SGMO News
- 5 weeks ago - Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 7 weeks ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call - GlobeNewsWire
- 5 months ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - GlobeNewsWire
- 5 months ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript - Seeking Alpha